Evidence map›Paper›PMID 29460025›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2018

Combined model-based and patient-specific dosimetry for

Donika Plyku, Esther Mena, Steven P Rowe, Martin A Lodge, Zsolt Szabo, Steve Y Cho, Martin G Pomper, George Sgouros, Robert F Hobbs

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. A Prospective Study onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Trial
  2. Article
  3. Dosimetry and optimal scan time of [European journal of nuclear medicine and molecular imaging · 2021
    Article
  4. Theranostics · 2020
    Review
  5. Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Donika PlykuThe Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Esther MenaThe Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Steven P RoweThe Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Martin A LodgeThe Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Zsolt SzaboThe Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Steve Y ChoThe Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Martin G PomperThe Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
George SgourosThe Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Robert F HobbsThe Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. rhobbs3@jhmi.edu.ORCID 0000-0002-1328-7114
Johns Hopkins University · USUniversity of Maryland, Baltimore · US

Funding

Theranostic Imaging of Metastatic Prostate CancerP50CA103175 · NCI · JOHNS HOPKINS UNIVERSITY · PI BARKER, PETER B · 2003 to 2015
$17.9M
Dose-Response in Radionuclide TherapyR01CA116477 · NCI · JOHNS HOPKINS UNIVERSITY · PI HOBBS, ROBERT FRANCOIS, SGOUROS, GEORGE · 2006 to 2022
$7.1M
PSMA-based Cancer Imaging AgentsR01CA134675 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI POMPER, MARTIN G · 2009 to 2025
$6.2M
Training for Clinician Scientists in Imaging ResearchT32EB006351 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI POMPER, MARTIN G · 2006 to 2022
$4.0M
Small Molecule PSMA-Targeted Alpha TherapyR01CA184228 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI POMPER, MARTIN G, ZALUTSKY, MICHAEL ROD · 2014 to 2023
$3.6M
Modeling Targeted Alpha Particle Therapy of CancerR01CA157542 · NCI · JOHNS HOPKINS UNIVERSITY · PI HOBBS, ROBERT FRANCOIS · 2012 to 2015
$1.3M
PSMA Directed Imaging of Prostate Cancer Focus on Androgen Receptor DynamicsU01CA183031 · NCI · JOHNS HOPKINS UNIVERSITY · PI DEWEESE, THEODORE L, POMPER, MARTIN G · 2015 to 2017
$1.2M
NCI NIH HHS P50 CA103175NCI NIH HHS R01 CA116477NCI NIH HHS R01 CA134675NCI NIH HHS R01 CA157542NCI NIH HHS R01 CA184228NCI NIH HHS U01 CA183031NIBIB NIH HHS T32 EB006351
6 · The paper itself

Abstract

purposeProstate-specific membrane antigen (PSMA), a type-II integral membrane protein highly expressed in prostate cancer, has been extensively used as a target for imaging and therapy. Among the available PET radiotracers, the low molecular weight agents that bind to PSMA are proving particularly effective. We present the dosimetry results for

methodsNine patients were imaged using sequential PET/CT scans at approximately 1, 12, 35 and 70 min, and a final PET/CT scan at approximately 120 min after intravenous administration of 321 ± 8 MBq (8.7 ± 0.2 mCi) of

resultsThe highest calculated mean AD per unit administered activity of

conclusions

Indexed as

Positron Emission Tomography Computed TomographyRadiopharmaceuticalsHumansLysineMalePositron-Emission TomographyProstatic NeoplasmsRadiometryTissue DistributionUrea2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acidLysineRadiopharmaceuticalsUrea18FDosimetryMonte-Carlo modelingPETProstate cancerPSMA

Identifiers

PMID29460025
PMCPMC5918228
OpenAlexW2790072731

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.